乳腺与妇科病理中免疫组化应用进展
本文综述乳腺与妇科病理中免疫组化染色的诊断、预后和预测应用,涵盖新旧病种的组织形态与染色模式及判读陷阱,并讨论子宫内膜错配修复、p53、HER2及乳腺ER、PR、HER2的更新指南推荐。
要点
- 免疫组化助乳腺与妇科肿瘤的诊断、分期及预后预测。
- 子宫内膜癌需评估错配修复、p53和HER2。
- 乳腺癌需评估ER、PR和HER2。
核心结论
- 乳腺与妇科病理中多种病变受益于免疫组化评估,可提供诊断、分期、预后和预测信息。
研究设计与样本
- 基于英文文献综述与作者在乳腺和妇科病理的一手经验。
主要发现
- 综述了乳腺与妇科病理中既定和新颖免疫组化染色的使用与判读。
- 描述了各病种的组织形态和免疫组化染色模式及判读陷阱。
关键数值与推荐
- 讨论了子宫内膜错配修复、p53和HER2的更新指南推荐辅助检测。
- 讨论了乳腺雌激素受体、孕激素受体和HER2的指南推荐检测。
临床怎么用
- 在乳腺与妇科病理诊断中应用免疫组化辅助诊断、分期及预后预测。
- 按更新指南对子宫内膜癌行错配修复、p53和HER2检测。
- 按指南对乳腺癌行ER、PR和HER2检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT.—: The use of immunohistochemical stains in breast and gynecologic pathology has become increasingly complex, with various diagnostic, prognostic, and predictive applications. OBJECTIVE.—: To provide an update and review of immunohistochemical stains used in the practice of breast and gynecologic pathology. Established and new entities are reviewed, with descriptions of histomorphology and immunohistochemical staining patterns and discussion of interpretive pitfalls. DATA SOURCES.—: Data were obtained from review of the English-language literature and firsthand experience of the authors in breast and gynecologic pathology. CONCLUSIONS.—: Many entities in breast and gynecologic pathology benefit from evaluation with various immunohistochemical stains. These studies not only aid in the diagnosis and staging of tumors but also can provide prognostic and predictive information. Updated guidelines for recommended ancillary studies such as mismatch repair, p53, and human epidermal growth factor receptor 2 (HER2) studies in endometrium, as well as estrogen and progesterone receptors and HER2 in breast, are discussed. Finally, the use and interpretation of established and novel immunohistochemical stains are discussed in various breast and gynecologic malignancies.
引用
- Jenkins TM, Mehr CR. Updates in the Use of Immunohistochemical Stains in Breast and Gynecologic Pathology. Arch Pathol Lab Med. 2024. PMID: 37406290. doi:10.5858/arpa.2022-0467-RA
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。